2021 Biopharma Outlook: Turning Uncertainty Into Opportunity

A singular focus on defeating COVID-19 will likely dominate the biopharma agenda at the beginning of 2021 and will determine how quickly the industry, and world, can bounce back to something like normalcy. New digital capabilities and learnings will continue to emerge as the pandemic ebbs, and strong industry balance sheets will keep the deal volume moving, according to experts and executives.

The year 2020 was chaotic, to put it charitably. It was a year that makes gazing into a happier future – past the COVID-19 related suffering and hardship, past continuing racial injustice, past the political and environmental onslaught – something of a welcome respite. Our problems are far from solved, making optimism sometimes difficult to muster and a happier future challenging, at times, to picture